307 related articles for article (PubMed ID: 20945091)
1. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
3. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
[TBL] [Abstract][Full Text] [Related]
5. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
Moliterni A; Tarenzi E; Capri G; Terenziani M; Bertuzzi A; Grasselli G; Agresti R; Piotti P; Greco M; Salvadori B; Pilotti S; Lombardi F; Valagussa P; Bonadonna G; Gianni L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-10-S17-14. PubMed ID: 9374085
[TBL] [Abstract][Full Text] [Related]
7. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Sugarman S; Wasserheit C; Hodgman E; Coglianese M; D'Alassandro A; Fornier M; Troso-Sandoval T; D'Andrea G; Drullinsky P; Lake D; George R; Mills N; Moynahan M; Smith J; Panageas K; Norton L; Hudis C
Breast Cancer Res Treat; 2009 Jun; 115(3):609-12. PubMed ID: 18751888
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B; Windsor S; Holston B; DiStasio S; Staugaard-Hahn C; Abrantes J; Kneuper-Hall R; Farber L; Orell J; Bober-Sorcinelli K; Haffty BG; Reiss M
Cancer J Sci Am; 1999; 5(4):224-9. PubMed ID: 10439168
[TBL] [Abstract][Full Text] [Related]
11. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
[TBL] [Abstract][Full Text] [Related]
12. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu].
Anan K; Mitsuyama S; Taniguchi H; Yamamoto Y; Fujiyoshi K; Tateishi T; Tamura K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1417-22. PubMed ID: 17033230
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML; Berry DA; Cirrincione C; Hudis C; Winer EP; Gradishar WJ; Davidson NE; Martino S; Livingston R; Ingle JN; Perez EA; Carpenter J; Hurd D; Holland JF; Smith BL; Sartor CI; Leung EH; Abrams J; Schilsky RL; Muss HB; Norton L
J Clin Oncol; 2003 Apr; 21(8):1431-9. PubMed ID: 12668651
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Zujewski JA; Eng-Wong J; O'Shaughnessy J; Venzon D; Chow C; Danforth D; Kohler DR; Cusack G; Riseberg D; Cowan KH
Breast Cancer Res Treat; 2003 Sep; 81(1):41-51. PubMed ID: 14531496
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
20. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
